KHA-CARI commentary on the KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease
Corresponding Author
Suetonia C Palmer
Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand
Cochrane Renal Group, Sydney, Australia
Correspondence:
Dr Suetonia Palmer, Department of Medicine, University of Otago Christchurch, PO Box 4345, Christchurch 8140, New Zealand. Email: [email protected]
Search for more papers by this authorGiovanni FM Strippoli
Cochrane Renal Group, Sydney, Australia
Sydney School of Public Health, University of Sydney, Australia
Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
Fondazione Mario Negri Sud, S. Maria Imbaro, Italy
Diaverum, Lund, Sweden
Search for more papers by this authorJonathan C Craig
Cochrane Renal Group, Sydney, Australia
Sydney School of Public Health, University of Sydney, Australia
Search for more papers by this authorCorresponding Author
Suetonia C Palmer
Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand
Cochrane Renal Group, Sydney, Australia
Correspondence:
Dr Suetonia Palmer, Department of Medicine, University of Otago Christchurch, PO Box 4345, Christchurch 8140, New Zealand. Email: [email protected]
Search for more papers by this authorGiovanni FM Strippoli
Cochrane Renal Group, Sydney, Australia
Sydney School of Public Health, University of Sydney, Australia
Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
Fondazione Mario Negri Sud, S. Maria Imbaro, Italy
Diaverum, Lund, Sweden
Search for more papers by this authorJonathan C Craig
Cochrane Renal Group, Sydney, Australia
Sydney School of Public Health, University of Sydney, Australia
Search for more papers by this author
References
- 1Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296–1305.
- 2Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 2005; 353: 238–248.
- 3Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 2011; 377: 2181–2192.
- 4Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 2009; 360: 1395–1407.
- 5Eckardt K, Kasiske B. Kidney disease: Improving global outcomes. Nat. Rev. Nephrol. 2009; 5: 650–657.
- 6 Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int. Suppl. 2013; 3: 259–305.
- 7Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-analysis. Ann. Intern. Med. 2012; 157: 263–275.
- 8Marshall T, Bryan S, Gill P, Greenfield S, Gutridge K. Predictors of patients' preferences for treatments to prevent heart disease. Heart 2006; 92: 1651–1655.
- 9KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am. J. Kidney Dis. 2007; 49 (2 Suppl 2): S12–154.
- 10 National Kidney Foundation. K/DOQI Clinical Prqactice Guidelines for mamagement of dyslipidemias in paitents with kidney disease. Am. J. Kidney Dis. 2003; 41 (Suppl 3): S1–S91.
- 11Stone N, Robinson J, Lichtenstein A et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129 (25 Suppl 2): S1–S45.
- 12Phoon R, Johnson D. Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: Lipid lowering therapy. In: Caring for Australasians with Renal Impairment guidelines. 2012. [Cited 5 May 2014.] Available from URL: http://www.cari.org.au/CKD/CKD%20early/Medical_Th_Lipid-lowering.pdf
- 13Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A. Monitoring cholesterol levels: Measurement error or true change? Ann. Intern. Med. 2008; 148: 656–661.
- 14Ezekowitz J, McAlister FA, Humphries KH et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J. Am. Coll. Cardiol. 2004; 44: 1587–1592.
- 15 National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. 2012.
- 16 New Zealand Guidelines Group. New Zealand Primary Care Handbook 2012, 3rd edn. Wellington: New Zealand Guidelines Group, 2012.
- 17Robson B, Purdie G. Hauora: Māori Standards of Health IV. A Study of the Years 2000–2005. BH Robson, R Harris (eds). Wellington: Te Ropu Rangahau Hauora a Eru Pomare, 2007.
- 18Mitka M. Ezetimibe prescribing fails to keep up with evidence. JAMA 2014; 311: 11279–11280.
- 19Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: A systematic review and meta-analysis. Ann. Intern. Med. 2012; 157: 251–262.
- 20Pilmore H, Dent H, Chang S, McDonald SP, Chadban SJ. Reduction in cardiovascular death after kidney transplantation. Transplantation 2010; 89: 851–857.
- 21Jun M, Zhu B, Tonelli M et al. Effects of fibrates in kidney disease: A systematic review and meta-analysis. J. Am. Coll. Cardiol. 2012; 60: 2061–2071.
Citing Literature
